Chemotherapy options for the elderly patient with advanced non-small cell lung cancer.
AffiliationDepartment of Medical Oncology, Cork University Hospital, Cork, Ireland., email@example.com
Antineoplastic Agents/*therapeutic use
Carcinoma, Non-Small-Cell Lung/*drug therapy
Clinical Trials as Topic
Lung Neoplasms/*drug therapy
MetadataShow full item record
AbstractCombination chemotherapy has been shown to improve overall survival compared with best supportive care in patients with advanced non-small cell lung cancer (NSCLC). The survival advantage is modest and was initially demonstrated with cisplatin-containing regimens in a large meta-analysis of randomized trials reported in 1995. Newer chemotherapy combinations have been shown to be better tolerated than older cisplatin-based combinations, and some trials have also shown greater efficacy and survival benefits with these newer combinations. Combination chemotherapy is, therefore, the currently accepted standard of care for patients with good performance statuses aged less than 70 years with advanced NSCLC. However, there are limited data from clinical trials to support the use of combination chemotherapy in elderly patients over 70 years of age with advanced NSCLC. Subgroup analyses of large randomized phase III trials suggest that elderly patients with good performance statuses do as well as younger patients treated with combination chemotherapy. There are few randomized trials reported that evaluate chemotherapy in patients aged greater than 70 years only. Based on data from trials performed by an Italian group, single-agent vinorelbine has been shown to have significant activity in elderly patients with advanced NSCLC and to be well tolerated by those patients with Eastern Cooperative Oncology Group performance statuses of two or less, with associated improvements in measures of global health.
- Vinorelbine: a review of its use in elderly patients with advanced non-small cell lung cancer.
- Authors: Curran MP, Plosker GL
- Issue date: 2002
- Chemotherapy in elderly patients with advanced lung cancer. Part II: Treatment of non-small cell lung cancer (NSCLC).
- Authors: Honecker F, Wedding U, Bokemeyer C, Interdisziplinäre Arbeitsgruppe Geriatrische Onkologie der DGHO/DGG.
- Issue date: 2004 Dec
- Optimizing first-line treatment options for patients with advanced NSCLC.
- Authors: Wakelee H, Belani CP
- Issue date: 2005
- Chemotherapy for non-small cell lung cancer: have we reached a new plateau?
- Authors: Shepherd FA
- Issue date: 1999 Feb
- Chemotherapy of advanced non small cell lung cancer in the elderly: an update.
- Authors: Gridelli C
- Issue date: 2000 Sep